Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05409066
Other study ID # M20-638
Secondary ID 2021-000169-34
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 20, 2022
Est. completion date June 16, 2030

Study information

Verified date April 2024
Source AbbVie
Contact ABBVIE CALL CENTER
Phone 844-663-3742
Email abbvieclinicaltrials@abbvie.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Enrollment to one of the groups is closed. Around 500 adult participants with R/R FL will be enrolled in approximately 300 sites across the world. Participants will receive R2 (375 mg/m^2 intravenous infusion of rituximab up to 5 cycles and oral capsules of 20 mg lenalidomide for up to 12 cycles) alone or in combination with subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date June 16, 2030
Est. primary completion date November 15, 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status score 0 to 2. - Participant has: - Fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrating positive lesion compatible with computed tomography (CT) or magnetic resonance image (MRI)-defined anatomical tumor sites AND - >= 1 measurable nodal lesion (long axis > 1.5 cm) or >= 1 measurable extra-nodal lesion (long axis > 1.0 cm) on CT scan or MRI. - Histologically confirmed classic follicular lymphoma (FL) [previously Grade 1 to 3a FL] stage II, III, or IV with no evidence of histologic transformation to an aggressive lymphoma and CD20+ disease on most recent representative tumor biopsy based on the pathology report. - Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy. (Participant who received only prior anti-CD20 mAb monotherapy and/or radiation therapy is not eligible.) - Eligible to receive R2 per investigator determination. Exclusion Criteria: - Documented refractoriness to lenalidomide. - Have lenalidomide exposure within 12 months prior to randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Epcoritamab
Subcutaneous Injection
Rituximab
Intravenous Infusion
Lenalidomide
Oral Capsules

Locations

Country Name City State
Argentina Cemic /Id# 229697 Ciudad Autonoma de Buenos Aire Ciudad Autonoma De Buenos Aires
Argentina Fundaleu /Id# 229700 Ciudad Autonoma de Buenos Aire Ciudad Autonoma De Buenos Aires
Argentina Hospital Privado Universitario - Hospital Privado Centro Medico de Cordoba S.A. /ID# 229701 Cordoba
Argentina Clinica de Nefrologia, Urologia y Enfermedades Cardiovasculares /ID# 232124 Santa Fe
Australia Royal Prince Alfred Hospital /ID# 239272 Camperdown New South Wales
Australia Townsville University Hospital /ID# 231124 Douglas Queensland
Australia Peninsula Private Hospital /ID# 238796 Frankston Victoria
Australia Nepean Hospital /ID# 239093 Kingswood New South Wales
Australia Fiona Stanley Hospital /ID# 231122 Murdoch Western Australia
Australia Hollywood Medical Centre /ID# 251789 Nedlands Western Australia
Australia Royal Perth Hospital /ID# 230456 Perth Western Australia
Austria Ordensklinikum Linz GmbH Elisabethinen /ID# 247510 Linz Oberoesterreich
Austria Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 228366 Salzburg
Austria Universitaetsklinikum St. Poelten /ID# 234015 Sankt Poelten Niederoesterreich
Belgium Uza /Id# 228521 Edegem Antwerpen
Belgium Hospital La Louviere Site Jolimont - Helora /ID# 228520 La Louvière Hainaut
Belgium Universitair Ziekenhuis Leuven /ID# 247780 Leuven Vlaams-Brabant
Belgium Groupe Sante CHC - Clinique du MontLegia /ID# 230415 Liege
Belgium Vitaz /Id# 228525 Sint-Niklaas Oost-Vlaanderen
Belgium AZ Turnhout - Campus Sint-Elisabeth /ID# 231628 Turnhout
Brazil Upeclin Fmb - Unesp /Id# 252912 Botucatu Sao Paulo
Brazil Hospital de Clinicas da Universidade Federal do Parana /ID# 228123 Curitiba Parana
Brazil Hospital Amaral Carvalho - Fundacao Doutor Amaral Carvalho /ID# 228129 Jaú Sao Paulo
Brazil Instituto Nacional de Cancer (INCA) /ID# 228706 Rio de Janeiro
Brazil Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 228127 Sao Paulo
Brazil Instituto D'Or de Pesquisa e Ensino - Regional Sao Paulo /ID# 252918 Sao Paulo
Brazil Instituto de Assistencia Medica ao Servidor Publico Estadual /ID# 230182 Sao Paulo
Brazil Real e Benemérita Associação Portuguesa de Beneficência /ID# 228121 Sao Paulo
Brazil Fundacao Antonio Prudente - AC Camargo Cancer Center /ID# 228130 São Paulo Sao Paulo
Canada Cross Cancer Institute /ID# 249080 Edmonton Alberta
Canada CSSS Alphonse-Desjardins, CHAU de Levis /ID# 229896 Levis Quebec
Canada CHUQ- Hôpital de l'Enfant-Jesus /ID# 231537 Quebec City Quebec
Canada CISSSBSL -Hopital regional de Rimouski /ID# 229894 Rimouski Quebec
Canada BC Cancer - Victoria /ID# 228850 Victoria British Columbia
China Peking University First Hospital /ID# 250517 Beijing Beijing
China Peking University Third Hospital /ID# 230885 Beijing Beijing
China Fujian Medical University Union Hospital /ID# 233919 Fuzhou Fujian
China Guangdong Provincial Peoples Hospital(Huifu Campus) /ID# 232512 Guangzhou Guangdong
China Nanfang Hospital of Southern Medical University /ID# 230383 Guangzhou Guangdong
China Sun Yat-Sen University Cancer Center /ID# 231463 Guangzhou Guangdong
China The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 230390 Hangzhou Zhejiang
China The second affiliated hospital of Zhejiang University school of medicine /ID# 231250 Hangzhou Zhejiang
China Zhejiang Cancer hospital /ID# 231389 Hangzhou Zhejiang
China Jiangxi Provincial Cancer Hospital /ID# 232507 Nanchang Jiangxi
China The First Affiliated Hospital of Nanchang University /ID# 231047 Nanchang Jiangxi
China Fudan University Cancer Hospital /ID# 250475 Shanghai Shanghai
China The First Hospital of China Medical University /ID# 232509 Shenyang Liaoning
China The First Affiliated Hospital of Soochow University /ID# 232511 Suzhou Jiangsu
China Tianjin Cancer Hospital /ID# 230876 Tianjin Tianjin
China Hubei Cancer Hospital /ID# 232255 Wuhan Hubei
China Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 234153 Wuhan Hubei
China The Affiliated Hospital of Xuzhou Medical College /ID# 232513 Xuzhou Jiangsu
Czechia Fakultni nemocnice Hradec Kralove /ID# 228269 Hradec Kralove
Czechia Duplicate_Fakultni Nemocnice v Motole /ID# 228272 Prague
Czechia Fakultni nemocnice Kralovske Vinohrady /ID# 228564 Praha
Czechia Vseobecna fakultni nemocnice v Praze /ID# 228565 Praha
Denmark Regionshospitalet Godstrup /ID# 227466 Herning Midtjylland
Denmark Sygehus Lillebalt, Vejle /ID# 227404 Vejle Syddanmark
France CHU de CAEN - Hopital de la Cote de Nacre /ID# 245929 Caen
France CHU Clermont-Ferrand /ID# 238676 Clermont Auvergne-Rhone-Alpes
France Hôpitaux Universitaires Henri Mondor - Hôpital Henri Mondor /ID# 230358 Créteil
France CHU Dijon /ID# 230354 Dijon Cote-d Or
France CHD Vendée- La Roche-sur-Yon - Les Oudairies /ID# 234095 La Roche Sur Yon
France CHRU Lille - Hopital Claude Huriez /ID# 230353 Lille Nord
France CHU Limoges - Dupuytren 1 /ID# 231450 Limoges CEDEX 1 Franche-Comte
France Centre Leon Berard /ID# 230348 Lyon CEDEX 08 Rhone
France CHU de Nantes, Hotel Dieu -HME /ID# 245928 Nantes Pays-de-la-Loire
France CHU NIMES - Hopital Caremeau /ID# 230351 Nimes CEDEX 9 Gard
France AP-HP - Hopital Saint-Louis /ID# 232067 Paris
France Hopital Pitie Salpetriere /ID# 230360 Paris
France CHU Bordeaux - Hopital Haut Leveque /ID# 230347 Pessac Gironde
France HCL - Hopital Lyon Sud /ID# 231449 Pierre Benite CEDEX Rhone
France CHU Poitiers - La miletrie /ID# 230357 Poitiers Vienne
France CHU Reims - Hôpital Robert Debre /ID# 248710 Reims CEDEX Marne
France CHU de Rennes - PONTCHAILLOU /ID# 230356 Rennes Bretagne
France IUCT Oncopole /ID# 233486 Toulouse Cedex 9
France CHRU Nancy - Hopitaux de Brabois /ID# 241595 Vandoeuvre-les-Nancy Meurthe-et-Moselle
Germany Sozialstiftung Bamberg /ID# 229184 Bamberg
Germany Helios Klinikum Berlin-Buch /ID# 229178 Berlin
Germany Universitaetsklinikum Bonn /ID# 249401 Bonn
Germany Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 229754 Dresden
Germany Universitaetsklinikum Essen /ID# 229180 Essen
Germany Universitaetsklinikum Giessen /ID# 234245 Gießen Hessen
Germany Universitaetsklinikum Jena /ID# 232064 Jena Thueringen
Germany Klinikum Kassel /ID# 229185 Kassel
Germany Universitaetsklinikum Leipzig /ID# 242907 Leipzig Sachsen
Germany Otto-von-Guericke-Universitaet /ID# 230144 Magdeburg
Germany Klinikum Mutterhaus der Borromäerinnen /ID# 232354 Trier
Germany Universitaetsklinikum Tuebingen /ID# 229663 Tubingen Baden-Wuerttemberg
Germany Universitaetsklinikum Wuerzburg /ID# 229278 Wuerzburg
Greece Alexandra General Hospital /ID# 226632 Athens Attiki
Greece General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 226633 Athens
Greece General Hospital of Athens Laiko /ID# 226626 Athens Attiki
Greece University General Hospital Attikon /ID# 226629 Athens Attiki
Greece University General Hospital of Ioannina /ID# 226628 Ioannina
Greece General University Hospital of Thessaloniki AXEPA /ID# 226630 Thessaloniki
Greece Theageneio Anticancer Hospital /ID# 226627 Thessaloniki
Hungary Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 229286 Budapest
Hungary Orszagos Onkologiai Intezet /ID# 229292 Budapest
Hungary Semmelweis Egyetem /ID# 229291 Budapest
Hungary Debreceni Egyetem-Klinikai Kozpont /ID# 229287 Debrecen Hajdu-Bihar
Hungary Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 246475 Kaposvár Somogy
Hungary Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz /ID# 232203 Nyiregyhaza Szabolcs-Szatmar-Bereg
Hungary Szegedi Tudományegyetem /ID# 229289 Szeged
Hungary Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 229290 Szombathely Vas
Israel Rabin Medical Center /ID# 228043 Haifa H_efa
Israel Rambam Health Care Campus /ID# 227849 Haifa H_efa
Israel Hadassah /ID# 227846 Jerusalem Yerushalayim
Israel The Chaim Sheba Medical Center /ID# 228322 Ramat Gan Tel-Aviv
Israel ZIV Medical Center /ID# 232257 Safed HaTsafon
Israel Tel Aviv Sourasky Medical Center /ID# 228529 Tel Aviv Tel-Aviv
Israel Assaf Harofeh Medical Center /ID# 228037 Zerifin HaMerkaz
Italy Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo /ID# 227401 Alessandria
Italy Centro di Riferimento Oncologico /ID# 227395 Aviano
Italy ASST Spedali civili di Brescia /ID# 227397 Brescia
Italy Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 229602 Candiolo Torino
Italy IEO -Istituto Europeo di Oncologia /ID# 227396 Milan Milano
Italy Ospedale San Raffaele IRCCS /ID# 228669 Milan Milano
Italy Azienda Ospedaliera Universitaria Federico II /ID# 230403 Napoli
Italy Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 227399 Novara
Italy A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 227402 Palermo
Italy Ospedale Santa Maria delle Croci /ID# 227394 Ravenna
Italy Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 230402 Rome Lazio
Italy Fondazione di Religione e di Culto Casa Sollievo della Sofferenza /ID# 228458 San Giovanni Rotondo Foggia
Italy AOU Citta della Salute e della Scienza di Torino /ID# 229820 Torino Piemonte
Japan National Cancer Center Hospital /ID# 230004 Chuo-ku Tokyo
Japan Kyushu University Hospital /ID# 230136 Fukuoka-shi Fukuoka
Japan National Hospital Organization Kyushu Cancer Center /ID# 252245 Fukuoka-shi Fukuoka
Japan Fukushima Medical University Hospital /ID# 251839 Fukushima-shi Fukushima
Japan Tokai University Hospital /ID# 252135 Isehara-shi Kanagawa
Japan Kagoshima University Hospital /ID# 232251 Kagoshima-shi Kagoshima
Japan National Cancer Center Hospital East /ID# 232423 Kashiwa-shi Chiba
Japan Kobe City Medical Center General Hospital /ID# 251945 Kobe-shi Hyogo
Japan The Cancer Institute Hospital Of JFCR /ID# 230271 Koto-ku Tokyo
Japan Kyoto University Hospital /ID# 231156 Kyoto-shi Kyoto
Japan Shinshu University Hospital /ID# 252246 Matsumoto-shi Nagano
Japan Matsuyama Red Cross Hospital /ID# 251866 Matsuyama-shi Ehime
Japan NHO Nagoya Medical Center /ID# 230678 Nagoya-shi Aichi
Japan Okayama University Hospital /ID# 232009 Okayama-shi Okayama
Japan Kindai University Hospital /ID# 232152 Osakasayama-shi Osaka
Japan Hokkaido University Hospital /ID# 231443 Sapporo-shi Hokkaido
Japan Tohoku University Hospital /ID# 232303 Sendai-shi Miyagi
Japan Mie University Hospital /ID# 251944 Tsu-shi Mie
Japan Yamagata University Hospital /ID# 230005 Yamagata-shi Yamagata
Korea, Republic of Dong-A University Hospital /ID# 228638 Busan
Korea, Republic of Inje University Busan Paik Hospital /ID# 230293 Busan
Korea, Republic of Pusan National University Hospital /ID# 229798 Busan
Korea, Republic of Keimyung University Dongsan Medical Center /ID# 229800 Daegu
Korea, Republic of Jeonbuk National University Hospital /ID# 228908 Jeonju
Korea, Republic of Seoul National University Bundang Hospital /ID# 228448 Seongnam-si Gyeonggido
Korea, Republic of Asan Medical Center /ID# 228444 Seoul Seoul Teugbyeolsi
Korea, Republic of Samsung Medical Center /ID# 228445 Seoul
Korea, Republic of Seoul National University Hospital /ID# 228446 Seoul
Korea, Republic of The Catholic University of Korea, Seoul St. Marys Hospital /ID# 228447 Seoul Seoul Teugbyeolsi
Netherlands Onze Lieve Vrouwe Gasthuis /ID# 247899 Amsterdam
Netherlands Amphia Ziekenhuis /ID# 247739 Breda
Netherlands Deventer Ziekenhuis /ID# 247853 Deventer
Netherlands Albert Schweitzer Ziekenhuis /ID# 247740 Dordrecht Zuid-Holland
Netherlands Medisch Spectrum Twente /ID# 247854 Enschede
Netherlands Admiraal de Ruyter Ziekenhuis /ID# 247692 Goes
Netherlands Universitair Medisch Centrum Groningen /ID# 247741 Groningen
Netherlands Dijklander Ziekenhuis /ID# 248993 Hoorn Nh Noord-Holland
Netherlands Leids Universitair Medisch Centrum /ID# 247742 Leiden
Netherlands St. Antonius Ziekenhuis /ID# 248644 Nieuwegein
Netherlands Canisius-Wilhelmina Ziekenhuis /ID# 248138 Nijmegen
Netherlands Franciscus Gasthuis & Vlietland, Locatie Gasthuis /ID# 248139 Rotterdam Zuid-Holland
New Zealand Palmerston North Hospital /ID# 232352 Palmerston North Manawatu-Wanganui
New Zealand Aotearoa Clinical Trials /ID# 228509 Papatoetoe Auckland
New Zealand North Shore Hospital /ID# 228508 Takapuna Auckland
Poland Szpitale Pomorskie Sp. z o.o /ID# 229122 Gdynia Pomorskie
Poland Swietokrzyskie Centrum Onkologii /ID# 229362 Kielce Swietokrzyskie
Poland Pratia MCM Krakow /ID# 229121 Krakow Malopolskie
Poland ARS-MEDICAL Sp. z o.o. /ID# 229601 Pila Wielkopolskie
Poland Centrum Medyczne Promed - Skorzewo /ID# 229299 Skorzewo Wielkopolskie
Puerto Rico Pan American Center for Oncology Trials, LLC /ID# 230055 Rio Piedras
South Africa University of Cape Town /ID# 228900 Cape Town Western Cape
South Africa Wits Clinical Research Site /ID# 228895 Johannesburg Gauteng
South Africa Haemalife Inc. /ID# 243392 Kuilsrivier Western Cape
South Africa Alberts Cellular Therapy /ID# 228896 Pretoria Gauteng
Spain Instituto Catalan de Oncologia (ICO) Badalona /ID# 228108 Badalona Barcelona
Spain Hospital Parc de Salut del Mar /ID# 228106 Barcelona
Spain Hospital Santa Creu i Sant Pau /ID# 229859 Barcelona
Spain Hospital San Pedro de Alcantara /ID# 248845 Caceres
Spain Hospital Universitario Reina Sofia /ID# 228122 Cordoba
Spain Instituto Catalan de Oncologia (ICO) L'Hospitalet /ID# 228107 Hospitalet de Llobregat Barcelona
Spain CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 229157 Madrid
Spain Hospital Universitario 12 de Octubre /ID# 228109 Madrid
Spain Hospital Universitario Fundacion Jimenez Diaz /ID# 228110 Madrid
Spain Hospital Universitario Ramon y Cajal /ID# 228113 Madrid
Spain MD Anderson Madrid /ID# 229860 Madrid
Spain Clinica Universidad de Navarra - Pamplona /ID# 228116 Pamplona Navarra
Spain Hospital Universitario de Salamanca /ID# 228117 Salamanca
Spain Hospital Universitario Marques de Valdecilla /ID# 228984 Santander Cantabria
Spain Hospital Universitario Virgen del Rocio /ID# 228118 Sevilla
Sweden Sodra Alvsborgs sjukhus /ID# 228886 Boras Vastra Gotalands Lan
Sweden Linkoping University Hospital /ID# 233520 Linkoping
Sweden Sunderby sjukhus /ID# 228165 Lulea Norrbottens Lan
Switzerland Kantonsspital Aarau AG /ID# 229113 Aarau Aargau
Switzerland EOC Ospedale Regionale di Bellinzona e Valli /ID# 228922 Bellinzona Ticino
Switzerland Kantonsspital Graubunden /ID# 253862 Chur Graubuenden
Switzerland Kantonsspital St. Gallen /ID# 229117 St. Gallen Sankt Gallen
Taiwan Kaohsiung Chang Gung Memorial Hospital /ID# 227384 Kaohsiung City Kaohsiung
Taiwan China Medical University Hospital /ID# 227379 Taichung
Taiwan Taichung Veterans General Hospital /ID# 227383 Taichung
Taiwan National Cheng Kung University Hospital /ID# 227381 Tainan
Turkey Ankara Universitesi Fakultesi /ID# 227790 Ankara
Turkey Akdeniz Universitesi Tip Fakul /ID# 227791 Antalya
Turkey Dicle Universitesi Tip /ID# 230087 Diyarbakir
Turkey Istanbul Florence Nightingale Hastanesi /ID# 229546 Istanbul
Turkey Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 248202 Istanbul
Turkey Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 227855 Istanbul
Turkey Ege University Medical Faculty /ID# 227792 Izmir
Turkey Kocaeli University Med Faculty /ID# 227854 Kocaeli
Turkey Ondokuz mayis University Facul /ID# 227794 Samsun
United Kingdom East Suffolk and North Essex NHS Foundation Trust /ID# 230040 Colchester
United Kingdom Leeds Teaching Hospitals NHS Trust /ID# 230471 Leeds
United Kingdom The Clatterbridge Cancer Centre NHS Foundation Trust /ID# 230036 Liverpool
United Kingdom Barts Health NHS Trust /ID# 230028 London London, City Of
United Kingdom The Christie Hospital /ID# 230124 Manchester
United Kingdom The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 230123 Newcastle upon Tyne
United Kingdom Oxford University Hospitals NHS Foundation Trust /ID# 230035 Oxford Oxfordshire
United Kingdom University Hospital Plymouth NHS Trust /ID# 230038 Plymouth
United States Intermountain Health - St Vincent Regional Hospital - Cancer Centers of Montana /ID# 251220 Billings Montana
United States St. Luke's Hospital - Chesterfield /ID# 247817 Chesterfield Missouri
United States Northwestern University Feinberg School of Medicine /ID# 227248 Chicago Illinois
United States Goshen Center for Cancer Care /ID# 227189 Goshen Indiana
United States Long Beach Memorial Medical Ct /ID# 228997 Long Beach California
United States University of Southern California /ID# 227195 Los Angeles California
United States Perlmutter Cancer Center at NYU Langone /ID# 253343 Mineola New York
United States Morristown Medical Center /ID# 231427 Morristown New Jersey
United States Laura and Isaac Perlmutter Cancer Center at NYU Langone /ID# 227322 New York New York
United States Memorial Sloan Kettering Cancer Center-Koch Center /ID# 227193 New York New York
United States University of Arizona Cancer Center - North Campus /ID# 228862 Tucson Arizona
United States UMass Memorial Medical Center /ID# 227323 Worcester Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
AbbVie Genmab

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Canada,  China,  Czechia,  Denmark,  France,  Germany,  Greece,  Hungary,  Israel,  Italy,  Japan,  Korea, Republic of,  Netherlands,  New Zealand,  Poland,  Puerto Rico,  South Africa,  Spain,  Sweden,  Switzerland,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-Free Survival (PFS) PFS is defined as duration from the date of randomization to the date of disease progression determined by Lugano criteria by independent review committee (IRC) or death (whichever occurs first). Up to approximately 5 years
Secondary Percentage of Participants Achieving Complete Response (CR) Percentage of participants who achieve a CR determined per Lugano criteria, as assessed by the IRC prior to the initiation of subsequent anti-lymphoma therapy. Up to approximately 5 years
Secondary Overall Survival (OS) Overall survival is defined as the duration from the date of randomization to the date of the participant's death. Up to approximately 8 years from randomization
Secondary Percentage of Participants Achieving Minimal Residual Disease (MRD) Negativity MRD negativity rate is defined as the percentage of participants who achieve MRD negative status prior to the initiation of subsequent anti-lymphoma therapy. Up to approximately 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT06043011 - Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Terminated NCT03571828 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Phase 1
Terminated NCT02914938 - A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Phase 1
Recruiting NCT05888493 - A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma Phase 3
Recruiting NCT04049513 - ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) Phase 1
Recruiting NCT06097364 - A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma Phase 3
Recruiting NCT03869619 - REal World Data in LYmphoma and Survival in Adults
Active, not recruiting NCT04830137 - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Phase 1
Recruiting NCT03547115 - A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML Phase 1
Not yet recruiting NCT04767308 - Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies Early Phase 1
Terminated NCT03768505 - Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) Phase 2
Recruiting NCT03265158 - Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 N/A
Enrolling by invitation NCT04488354 - Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T Phase 1
Recruiting NCT05720052 - A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT06191744 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Phase 3
Active, not recruiting NCT02362035 - ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT06091254 - A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma Phase 3
Enrolling by invitation NCT02875548 - A Study to Assess the Long-term Safety of Tazemetostat Phase 1/Phase 2
Active, not recruiting NCT04450069 - CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies Phase 1
Terminated NCT04745832 - Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Phase 3

External Links